CA2284820A1 - Nouvelle utilisation de l'antithrombine iii - Google Patents

Nouvelle utilisation de l'antithrombine iii Download PDF

Info

Publication number
CA2284820A1
CA2284820A1 CA002284820A CA2284820A CA2284820A1 CA 2284820 A1 CA2284820 A1 CA 2284820A1 CA 002284820 A CA002284820 A CA 002284820A CA 2284820 A CA2284820 A CA 2284820A CA 2284820 A1 CA2284820 A1 CA 2284820A1
Authority
CA
Canada
Prior art keywords
iii
preparation
heparin
use according
heparins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002284820A
Other languages
English (en)
Inventor
Hans-Peter Schwarz
Anton Philapitsch
Ludwig Pichler
Wilfried Auer
Yendra Linnau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter Aktiengesellschaft
Hans-Peter Schwarz
Anton Philapitsch
Ludwig Pichler
Wilfried Auer
Yendra Linnau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Aktiengesellschaft, Hans-Peter Schwarz, Anton Philapitsch, Ludwig Pichler, Wilfried Auer, Yendra Linnau filed Critical Baxter Aktiengesellschaft
Publication of CA2284820A1 publication Critical patent/CA2284820A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002284820A 1997-03-25 1998-03-24 Nouvelle utilisation de l'antithrombine iii Abandoned CA2284820A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT51797A AT405905B (de) 1997-03-25 1997-03-25 Neue verwendung von antithrombin iii
ATA517/97 1997-03-25
PCT/AT1998/000078 WO1998042371A1 (fr) 1997-03-25 1998-03-24 Nouvelle utilisation d'antithrombine iii

Publications (1)

Publication Number Publication Date
CA2284820A1 true CA2284820A1 (fr) 1998-10-01

Family

ID=3492718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284820A Abandoned CA2284820A1 (fr) 1997-03-25 1998-03-24 Nouvelle utilisation de l'antithrombine iii

Country Status (5)

Country Link
EP (1) EP0971732A1 (fr)
AT (1) AT405905B (fr)
AU (1) AU6385298A (fr)
CA (1) CA2284820A1 (fr)
WO (1) WO1998042371A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012012460B1 (pt) * 2009-11-24 2020-06-23 Grifols Therapeutics Inc. Método de liofilização de uma composição

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3170001D1 (en) * 1980-09-30 1985-05-23 Bayer Ag Method for the production of an antithrombin-heparin complex and pharmaceutical compositions containing the complex
US4689323A (en) * 1983-09-26 1987-08-25 Miles Laboratories, Inc. Covalently bound heparin--antithrombin-III complex
JP3494667B2 (ja) * 1992-10-02 2004-02-09 アベンティス ファーマ株式会社 アンチトロンビンｉｉｉ製剤
JP3820607B2 (ja) * 1995-11-10 2006-09-13 三菱ウェルファーマ株式会社 アンチトロンビン−ｉｉｉの液状製剤およびその保存安定化方法
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途

Also Published As

Publication number Publication date
AT405905B (de) 1999-12-27
WO1998042371A1 (fr) 1998-10-01
AU6385298A (en) 1998-10-20
ATA51797A (de) 1999-05-15
EP0971732A1 (fr) 2000-01-19

Similar Documents

Publication Publication Date Title
US5691312A (en) Pharmaceutical for subcutaneous or intramuscular administration containing polypeptides
Mombelli et al. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction.
RU2252783C2 (ru) Фармацевтический препарат, содержащий низкомолекулярный ингибитор тромбина и его пролекарство
JPS6036414A (ja) 口鼻咽粘膜用医薬
JPH04504710A (ja) 抗血栓組成物
EP1226829A2 (fr) Préparations liquides stabilisées de la protéase ou de son proenzyme qui activent le facteur VII de la coagulation sanguine
AU696954B2 (en) Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
Mariani et al. Treatment of congenital factor VII deficiency with a new concentrate
Tibballs et al. The cardiovascular and haematological effects of purified prothrombin activator from the common brown snake (Pseudonaja textilis) and their antagonism with heparin
KR100416677B1 (ko) 트롬빈억제제를함유하는주입용저장안정성수용액
US5767106A (en) Treatment of disease and conditions associated with macrophage infiltration
CA2284820A1 (fr) Nouvelle utilisation de l'antithrombine iii
WO1996005845A2 (fr) Traitement de maladies et de troubles associes a des infiltrations de macrophages, notamment les apoplexies et les infarctus du myocarde
CA2062388A1 (fr) Methode et preparation pour l'inhibition ou la prevention des metastases cancereuses
US20070275086A1 (en) Use of Increased Molecular-Weight Hirudin as an Anticoagulant in Extracorporeal Kidney Replace Therapy
WO1992020361A1 (fr) Nouvelle combinaison de facteur viii et d'un antifibrinolytique
Brill-Edwards et al. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: Implications for antithrombotic therapy
JPS63503542A (ja) 新規組成物
EP0733371B1 (fr) Agent pour l'application sous-coutanée de la protéine C
Peternel et al. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models
Arnesen et al. What is the optimal dosage of LMW heparin in the SC treatment of deep venous thrombosis
Soulier et al. In vivo attempt to consume antithrombin III by iv injection of a thrombin-heparin mixture
Köhler et al. Intravenous and subcutaneous desmopressin: clinical results
Gallus et al. The influence of Org 10172, an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy
CN1292793C (zh) 人尿激肽原酶在制备脓毒症药物中的应用

Legal Events

Date Code Title Description
FZDE Discontinued